Crossref
Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients
Advances in Oncology · 2026-05 · 6 (1) · 145-163
DOI: 10.1016/j.yao.2026.01.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Oncology, 2026-05. Verfasst von Anahid Hamparsumian und 2 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hamparsumian, A., Sitlinger, A., & Brander, D. M. (2026). Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients. Advances in Oncology, 6(1), 145-163. https://doi.org/10.1016/j.yao.2026.01.015
Vancouver
Hamparsumian A, Sitlinger A, Brander DM. Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients. Advances in Oncology. 2026;6(1):145-163. doi:10.1016/j.yao.2026.01.015
BibTeX
@article{Hamparsumian2026,
author = {Hamparsumian, Anahid and Sitlinger, Andrea and Brander, Danielle M.},
title = {Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients},
journal = {Advances in Oncology},
year = {2026},
volume = {6},
number = {1},
pages = {145--163},
doi = {10.1016/j.yao.2026.01.015}
}
EUVIMED